Amgen Director Receives Routine Stock Grant (AMGN)
AMGEN INC
Subscribe to track AMGN
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Amgen Director Receives Routine Stock Grant (AMGN)
Company: AMGEN INC (AMGN) Form: 4 | Filed: 2025/11/12 Significance: Low
Insider: Drake Michael V Title: null | Relationship: Director
Transaction: • Type: Grant • Shares: 218.6134 • Price: $0.00 • Value: $0 • Owned After: 4,958.6425
Key Insight: This is a routine, non-cash grant of dividend equivalents on previously vested RSUs, not an open-market transaction.
Market Context: The transaction is immaterial, representing less than 0.0001% of shares outstanding for the $174.28B biotech company.
Comprehensive Analysis
SEC Filing Analysis: AMGEN INC (AMGN)
Executive Summary
- Trading Significance: Low
- Key Takeaway: A director received a minor, non-cash stock grant in the form of dividend equivalents, a routine event with no market-moving implications.
- Market Impact: Neutral. The transaction is negligible in size and value.
Company Information
| Field | Value |
|---|---|
| Company | AMGEN INC |
| Ticker Symbol | AMGN |
| CIK | 0000318154 |
| Industry | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
Insider Information
| Field | Value |
|---|---|
| Name | Drake Michael V |
| CIK | 0001938942 |
| Title/Position | null |
| Relationship | Director |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-11-07 |
| Transaction Code | A (Award/Grant) |
| Security Type | Common Stock |
| Shares Involved | 218.6134 |
| Price Per Share | $0.00 |
| Total Value | $0 |
| Shares Owned After | 4,958.6425 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $0 |
| % of Market Cap | 0.0000% |
| Shares Transacted | 218.6134 |
| % of Shares Outstanding | 0.00004% |
| Post-Transaction Ownership | 4,958.6425 shares (0.0009% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: The transaction has a value of $0 and is therefore insignificant against Amgen's $174.28 billion market capitalization.
- Ownership Concentration: The insider's total holdings remain extremely small, at less than 0.001% of total shares outstanding.
- Dilution Impact: The issuance of 218 shares has a negligible dilutive effect on the 538.4 million shares outstanding.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: This is a routine, non-market transaction with zero monetary value, common for director compensation. It does not signal any change in insider sentiment.
Volume & Sentiment
- Expected Volume Impact: None. This was not an open-market transaction.
- Sentiment Indicator: Neutral. The filing is procedural and provides no new information to influence market sentiment.
Additional Context
Transaction Notes
- Special Circumstances: The filing's footnote clarifies that these shares are Dividend Equivalents (DEs) granted on the director's vested but deferred Restricted Stock Units (RSUs). This is a standard part of a director compensation program and not an active investment decision.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.